ID   PC-9/ER3
AC   CVCL_D726
SY   PC-9-ER3
DR   cancercelllines; CVCL_D726
DR   Cosmic; 1745415
DR   Wikidata; Q54938491
RX   PubMed=22712764;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=22712764; DOI=10.1111/j.1349-7006.2012.02363.x;
RA   Harada D., Takigawa N., Ochi N., Ninomiya T., Yasugi M., Kubo T.,
RA   Takeda H., Ichihara E., Ohashi K., Takata S., Tanimoto M., Kiura K.;
RT   "JAK2-related pathway induces acquired erlotinib resistance in lung
RT   cancer cells harboring an epidermal growth factor receptor-activating
RT   mutation.";
RL   Cancer Sci. 103:1795-1802(2012).
//